Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$56.80 USD

56.80
926,406

-0.58 (-1.01%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $56.82 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CYTK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 615 783 472 464 225
Receivables 1 0 52 4 5
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 12 12 12 6 3
Total Current Assets 628 795 536 474 234
Net Property & Equipment 69 80 73 13 5
Investments & Advances 41 47 152 37 43
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 8 10 7 0 0
Total Assets 824 1,015 841 534 290
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 22 26 21 8 8
Current Portion Long-Term Debt 10 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 43 44 34 19 12
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 11 2 2 1 1
Total Current Liabilities 103 85 72 31 26
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 87 87 0
Convertible Debt 549 546 95 90 84
Long-Term Debt 58 64 47 46 45
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 380 302 184 166 143
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,211 1,123 597 420 301
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,726 1,482 1,452 1,105 853
Retained Earnings -2,112 -1,586 -1,208 -992 -865
Other Equity 0 -4 -1 0 1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -386 -108 244 113 -11
Total Liabilities & Shareholder's Equity 824 1,015 841 534 290
Total Common Equity -386 -108 244 113 -11
Shares Outstanding 98.00 94.60 83.80 70.70 59.00
Book Value Per Share -3.94 -1.14 2.91 1.60 -0.19

Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 619 615 539 566
Receivables NA 1 1 3 1
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 19 12 20 20
Total Current Assets NA 639 628 561 587
Net Property & Equipment NA 68 69 76 77
Investments & Advances NA 15 41 15 27
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 8 8 8 8
Total Assets NA 808 824 741 780
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 13 22 14 13
Current Portion Long-Term Debt NA 12 10 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 40 43 33 31
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 6 11 14 6
Total Current Liabilities NA 89 103 78 66
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 550 549 548 547
Long-Term Debt NA 57 58 61 62
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 380 370 314
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,204 1,211 1,179 1,113
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,852 1,726 1,537 1,514
Retained Earnings NA -2,248 -2,112 -1,975 -1,846
Other Equity NA -1 0 -1 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -396 -386 -439 -333
Total Liabilities & Shareholder's Equity NA 808 824 741 780
Total Common Equity 0 -396 -386 -439 -333
Shares Outstanding 104.80 104.50 98.00 96.00 95.60
Book Value Per Share 0.00 -3.79 -3.94 -4.57 -3.48